Within the oncology area, BioTrends provides comprehensive coverage across several commercially relevant markets with high unmet need. Our analysis includes up-to-date market research in both solid-tumor oncology and hematology-oncology indications. We currently focus our attention on malignant melanoma, prostate cancer, non-small-cell lung-cancer, and multiple myeloma. Through coverage of major new product launches in oncology (including Zytiga, Zelboraf, Yervoy, and Xalkori) we benchmark product penetration into these patient populations and capture an accurate reflection of true market dynamics. BioTrends oncology allows clients to understand oncologists’ shifting attitudes and prescribing practices in these increasingly crowded and heterogeneous markets.
We plan to widen our scope through 2012 to include analysis of other highly competitive oncology indications and coverage of additional launches of major brands within oncology markets. If you are interested in providing feedback on future BioTrends Oncology offerings please feel free to
contact us directly.
If you don't find a topic or disease in our list of publications, please call 610-321-9400 or email us so that we can guide you to related or upcoming coverage or to discuss a customized project.